ERT and Bioclinica to Merge

Article

ERT has announced that Bioclinica has agreed to merge with ERT. The transaction will integrate Bioclinica’s knowledge in imaging, with ERT’s knowledge in eCOA, cardiac safety, respiratory and wearables.

Euan Menzies, CEO of Bioclinica, said, “The combination will make us a more relevant partner to an even broader group of clients operating in today’s complex and fast-moving clinical trials environment. We look forward to leveraging our new footprint together in the chapters ahead.”

Joe Eazor will be the CEO of the newly merged company and the management team will be composed of a combination of both ERT and Bioclinica executives.

The proposed transaction is subject to customary closing conditions, including approval by regulatory agencies. ERT and Bioclinica expect the transaction to close in 2021.

For more information, click here.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.